T0	KEYPHRASE-NOTYPES 0 11	Conclusions,"","fro"
T1	KEYPHRASE-NOTYPES 22 27	study,"his","are"
T2	KEYPHRASE-NOTYPES 46 72	primary efficacy end point,"the","of "
T3	KEYPHRASE-NOTYPES 76 80	week," of","12,"
T4	KEYPHRASE-NOTYPES 88 109	ceftriaxone treatment," IV","res"
T5	KEYPHRASE-NOTYPES 130 141	improvement,"ter","in "
T6	KEYPHRASE-NOTYPES 145 154	cognition," in","and"
T7	KEYPHRASE-NOTYPES 188 208	physical functioning," in"," pa"
T8	KEYPHRASE-NOTYPES 210 214	pain,"ng,"," an"
T9	KEYPHRASE-NOTYPES 220 227	fatigue,"and"," Cl"
T10	KEYPHRASE-NOTYPES 229 250	Clinical significance,"ue."," ho"
T11	KEYPHRASE-NOTYPES 272 289	long-term effects," on"," No"
T12	KEYPHRASE-NOTYPES 308 326	long-term benefits,"the","for"
T13	KEYPHRASE-NOTYPES 335 352	ceftriaxone group,"the","on "
T14	KEYPHRASE-NOTYPES 356 376	physical functioning," on","and"
T15	KEYPHRASE-NOTYPES 381 385	pain,"and","amo"
T16	KEYPHRASE-NOTYPES 419 427	patients,"ted","at "
T17	KEYPHRASE-NOTYPES 431 439	baseline," at"," be"
T18	KEYPHRASE-NOTYPES 474 491	troubling aspects,"ost","of "
T19	KEYPHRASE-NOTYPES 495 521	posttreatment Lyme disease," of"," [2"
T20	KEYPHRASE-NOTYPES 541 557	primary interest,"our","in "
T21	KEYPHRASE-NOTYPES 566 571	study,"his","was"
T22	KEYPHRASE-NOTYPES 579 588	cognition," on"," fo"
T23	KEYPHRASE-NOTYPES 604 615	improvement,"the","was"
T24	KEYPHRASE-NOTYPES 637 641	week," to","24."
T25	KEYPHRASE-NOTYPES 655 670	adverse effects,"er,","att"
T26	KEYPHRASE-NOTYPES 688 699	ceftriaxone," IV","occ"
T27	KEYPHRASE-NOTYPES 719 727	patients," of"," Th"
T28	KEYPHRASE-NOTYPES 761 777	limited duration,"the","of "
T29	KEYPHRASE-NOTYPES 781 802	cognitive improvement," of","and"
T30	KEYPHRASE-NOTYPES 811 816	risks,"the"," 10"
T31	KEYPHRASE-NOTYPES 821 826	weeks," 10","of "
T32	KEYPHRASE-NOTYPES 833 844	ceftriaxone," IV","and"
T33	KEYPHRASE-NOTYPES 857 862	weeks," 14","of "
T34	KEYPHRASE-NOTYPES 890 908	effective strategy," an","for"
T35	KEYPHRASE-NOTYPES 913 944	sustained cognitive improvement,"for"," Al"
T36	KEYPHRASE-NOTYPES 955 972	certain subgroups,"ugh","(pa"
T37	KEYPHRASE-NOTYPES 974 982	patients,"ps ","wit"
T38	KEYPHRASE-NOTYPES 1002 1026	neurologic abnormalities," or"," ma"
T39	KEYPHRASE-NOTYPES 1043 1060	long-term benefit,"nce","fro"
T40	KEYPHRASE-NOTYPES 1066 1077	ceftriaxone,"rom"," th"
T41	KEYPHRASE-NOTYPES 1083 1101	predictor analyses,"the","wer"
T42	KEYPHRASE-NOTYPES 1131 1141	hypothesis,"han","dri"
T43	KEYPHRASE-NOTYPES 1167 1191	independent confirmation,"ire"," Pe"
T44	KEYPHRASE-NOTYPES 1201 1218	confirmation,"ing"," tr"
T45	KEYPHRASE-NOTYPES 1220 1240	treatment strategies,"on,","tha"
